-Robert G Maki Researcher Activity Profile

Research Author Detailed Information 

Robert G Maki Publication Rate By Year

Robert G Maki has published 16 paper(s) in 2007, 4 paper(s) in 2008, for a total of 20 research publications in total.

Robert G Rg Maki Author Information

LAST NAME: maki

FIRST NAME: Robert G

INITIALS: rg

AFFILIATION:

Papers

Robert G Maki's Publication Record

1. Recent advances in therapy for gastrointestinal stromal tumors. Year Published: 2007
Melanoma-Sarcoma Service, Department of Medcine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA.
2. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Year Published: 2007
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. dematter@mskcc.org
3. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Year Published: 2007
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
4. Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Year Published: 2007
5. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Year Published: 2007
Gynecological Oncology Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
6. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Year Published: 2007
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
7. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Year Published: 2007
Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA.
8. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Year Published: 2007
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA. makir@mskcc.org
9. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Year Published: 2007
Department of Pathology, Memorial Sloan-Kettering Cancer Center, NY 10021, USA.
10. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Year Published: 2007
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, New York 10021-6007, USA. makir@mskcc.org.
11. Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Year Published: 2007
12. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Year Published: 2007
Division of Surgical Oncology, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
13. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Year Published: 2007
Department of Medicine, Columbia University, New York, New York 10032, USA. im17@columbia.edu
14. Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Year Published: 2007
15. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Year Published: 2007
Division of Surgical Oncology, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
16. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Year Published: 2008
Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L-586, Portland, OR 97239, USA. blankec@ohsu.edu
17. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Year Published: 2008
Oregon Health & Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L-586, Portland, OR 97239, USA. blankec@ohsu.edu
18. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. Year Published: 2008
19. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Year Published: 2008
Vice-Chair, Department of Pathology, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St. Nicholas Ave., Room 309, New York, NY 10032. cc2791@columbia.edu.
20. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Year Published: 2007
Department of Medicine, Columbia University, New York, New York 10032, USA. im17@columbia.edu